$-0.21
(Market cap
$0 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-18.6
-
Face value
--
-
Shares outstanding
1,394,671
6 Years Aggregate
CFO
$-185.35 Mln
EBITDA
$-203.68 Mln
Net Profit
$365.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neximmune Inc (NEXI)
| -- | -- | -- | -- | -97.3 | -94.9 | -- |
|
BSE Sensex*
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Neximmune Inc (NEXI)
| -63.5 | -94.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neximmune Inc (NEXI)
|
0.0 | 0.0 | 2.1 | -20.6 | -630.9 | -930.7 | -- | 0.0 |
| 88.8 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 79.0 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.0 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 106.4 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 356.9 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 544.5 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 617.6 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 371.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.0 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Neximmune Inc (NEXI)
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell... immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Read more
-
CEO, President & Director
Ms. Kristi Jones R.Ph.
-
CEO, President & Director
Ms. Kristi Jones R.Ph.
-
Headquarters
Gaithersburg, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Neximmune Inc (NEXI)
What is the current share price of Neximmune Inc (NEXI) Today?
The share price of Neximmune Inc (NEXI) is $0.00 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Neximmune Inc (NEXI) has given a return of -97.29% in the last 3 years.
What is the current PB & PE ratio of Neximmune Inc (NEXI)?
Since, TTM earnings of Neximmune Inc (NEXI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.07 |
0.67 |
2022 |
0.00 |
0.01 |
2021 |
-0.08 |
0.05 |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Neximmune Inc (NEXI)?
The 52-week high and low of Neximmune Inc (NEXI) are Rs 0.00 and Rs 0.00 as of 28-Aug-2026.
What is the market cap of Neximmune Inc (NEXI)?
Neximmune Inc (NEXI) has a market capitalisation of $ 0 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Neximmune Inc (NEXI)?
Before investing in Neximmune Inc (NEXI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.